Premium
Nucleoside‐modified messenger RNA COVID‐19 vaccine platform
Author(s) -
Roncati Luca,
Corsi Lorenzo
Publication year - 2021
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.26924
Subject(s) - virology , pandemic , virus , biology , vector (molecular biology) , nucleoside analogue , rna , dna vaccination , covid-19 , medicine , nucleoside , infectious disease (medical specialty) , immune system , immunology , disease , immunization , gene , genetics , pathology , recombinant dna
On March 11, 2020, the World Health Organization declared coronavirus disease 2019 (COVID‐19) a pandemic; from that date, the vaccine race has begun, and many technology platforms to develop a specific and effective COVID‐19 vaccine have been launched in several clinical trials (protein subunit, RNA‐based, DNA‐based, replicating viral vector, nonreplicating viral vector, inactivated virus, live attenuated virus, and virus‐like particle). Among the next‐generation strategies, nucleoside‐modified messenger RNA vaccines appear the most attractive, not only to counteract emerging pathogens but also for the possible applications in regenerative medicine and cancer therapy. However, exactly as all innovative drugs, they deserve careful pharmacovigilance in the short and long term.